First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience

Georg Jeryczynski; Marlies Antlanger; Franz Duca; Christina Binder-Rodriguez; Thomas Reiter; Ingrid Simonitsch-Klupp; Diana Bondermann; et al.

doi:10.1016/j.esmoop.2021.100065

First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience

Georg Jeryczynski
, Marlies Antlanger
, Franz Duca
, Christina Binder-Rodriguez
, Thomas Reiter
, Ingrid Simonitsch-Klupp
, Diana Bondermann
, et al.

Department of Internal Medicine 2 - Gastroenterology and Hepatology, Endocrinology and Metabolism, Nephrology, Rheumatology

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	100065
Number of pages	1
Journal	ESMO Open
Volume	6
Issue number	2
DOIs	https://doi.org/10.1016/j.esmoop.2021.100065
Publication status	Published - Apr 2021

Fields of science

303 Health Sciences
304 Medical Biotechnology
305 Other Human Medicine, Health Sciences
301 Medical-Theoretical Sciences, Pharmacy
302 Clinical Medicine

Access to Document

10.1016/j.esmoop.2021.100065

Cite this

@article{e226afa3453a4f3b9c3bfb52be629f06,

title = "First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience",

author = "Georg Jeryczynski and Marlies Antlanger and Franz Duca and Christina Binder-Rodriguez and Thomas Reiter and Ingrid Simonitsch-Klupp and Diana Bondermann and \{et al.\}",

year = "2021",

month = apr,

doi = "10.1016/j.esmoop.2021.100065",

language = "English",

volume = "6",

journal = "ESMO Open",

issn = "2059-7029",

number = "2",

}

TY - JOUR

T1 - First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience

AU - Jeryczynski, Georg

AU - Antlanger, Marlies

AU - Duca, Franz

AU - Binder-Rodriguez, Christina

AU - Reiter, Thomas

AU - Simonitsch-Klupp, Ingrid

AU - Bondermann, Diana

AU - et al., null

PY - 2021/4

Y1 - 2021/4

UR - https://www.scopus.com/pages/publications/85105895663

U2 - 10.1016/j.esmoop.2021.100065

DO - 10.1016/j.esmoop.2021.100065

M3 - Article

C2 - 33667762

SN - 2059-7029

VL - 6

JO - ESMO Open

JF - ESMO Open

IS - 2

M1 - 100065

ER -

First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience

Fields of science

Access to Document

Other files and links

Cite this